MQS Management LLC Buys Shares of 2,409 Cencora, Inc. $COR

MQS Management LLC bought a new stake in Cencora, Inc. (NYSE:CORFree Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,409 shares of the company’s stock, valued at approximately $814,000.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Cencora by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after acquiring an additional 221,570 shares during the last quarter. State Street Corp boosted its stake in shares of Cencora by 9.3% during the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after acquiring an additional 782,911 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Cencora by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after acquiring an additional 821,098 shares during the last quarter. Boston Partners boosted its stake in shares of Cencora by 2.0% during the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after acquiring an additional 89,506 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Cencora by 3.0% during the third quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company’s stock valued at $1,241,094,000 after acquiring an additional 115,278 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Up 3.6%

Shares of NYSE:COR opened at $275.01 on Friday. The stock’s 50-day moving average price is $305.70 and its two-hundred day moving average price is $336.77. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54. The firm has a market cap of $53.51 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 1.22 and a beta of 0.64.

Cencora (NYSE:CORGet Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same period in the previous year, the business posted $4.42 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, research analysts forecast that Cencora, Inc. will post 17.76 EPS for the current year.

Cencora announced that its Board of Directors has initiated a share repurchase program on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Robert W. Baird decreased their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Citigroup decreased their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. JPMorgan Chase & Co. increased their price objective on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Finally, Evercore set a $360.00 price objective on Cencora in a research note on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus price target of $380.25.

Read Our Latest Stock Analysis on Cencora

Cencora Company Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Featured Stories

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.